文献速递炎症性肠病

他克莫司在炎症性肠病中诱导短期而非长期临床应答

Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-03-17

UC患者部分Mayo评分中位数从6降至3,CD患者Harvey-Bradshaw指数从9降至7;但84%患者最终停药,34%出现治疗相关不良事件,长期疗效有限。

要点

  • 他克莫司治疗3个月可改善UC和CD的临床活动度评分。
  • CD诱导期血药浓度>10 ng/mL及联用硫嘌呤与3个月时较低疾病活动度相关。
  • 长期疗效有限且不良事件常见,84%患者最终停药。

核心结论

  • 他克莫司在CD和UC治疗3个月后均显示临床获益,但长期有效性和频繁不良事件仍是临床实践中的重要问题。

研究设计与样本

  • 西班牙22个中心的回顾性、多中心研究,纳入所有接受口服他克莫司治疗管腔或肛周IBD的成人患者。

主要发现

  • UC患者(n=58)部分Mayo评分中位数在3个月后从6降至3(P=0.0001)。
  • CD患者(n=85)Harvey-Bradshaw指数中位数在3个月后从9降至7(P=0.011)。
  • CD患者中,诱导期血他克莫司浓度>10 ng/mL vs <10 ng/mL(OR 0.23,95%CI 0.05-0.87)及联用硫嘌呤(OR 0.18,95%CI 0.04-0.81)与3个月时较低临床疾病活动度相关。
  • 62例肛周疾病患者中,8%(n=5)肛瘘完全闭合,34%(n=21)部分应答。
  • 治疗中位维持6个月(IQR 2-16),中位临床随访24个月(IQR 15-57)期间,治疗相关不良事件发生率34%,与血药浓度相关(P=0.021)。

临床怎么用

  • 他克莫司可用于IBD短期诱导治疗,尤其CD患者诱导期血药浓度>10 ng/mL及联用硫嘌呤可能与3个月较低疾病活动度相关。
  • 治疗期间需监测血药浓度及不良事件,并注意长期疗效有限且多数患者最终停药。

局限性

  • 回顾性、多中心设计,可能存在选择偏倚和信息偏倚。
  • 未设对照组,无法直接比较他克莫司与其他治疗的疗效差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). AIMS: To evaluate the efficacy and safety of tacrolimus in patients with IBD in clinical practice. METHODS: We performed a retrospective, multicentre study in 22 centres in Spain. All adult patients who received oral tacrolimus for luminal or perianal IBD were included. Clinical response was assessed by Harvey-Bradshaw index and partial Mayo score after 3 months. Perianal disease was evaluated by fistula drainage assessment. RESULTS: One hundred and forty-three patients were included (mean age 38 years; 51% male; median disease duration 110 months). In ulcerative colitis (UC) (n = 58), the partial Mayo score decreased after 3 months from median 6 to 3 (P = 0.0001), whereas in Crohn's disease (CD) (n = 85), the Harvey-Bradshaw index decreased after 3 months from median 9 to 7 (P = 0.011). In CD patients, blood tacrolimus concentrations during induction (>10 ng/mL vs <10 ng/mL; odds ratio 0.23, 95% CI 0.05-0.87) and the concomitant use of thiopurines (odds ratio 0.18, 95% CI 0.04-0.81) were associated with lower clinical disease activity at 3 months. Of 62 patients with perianal disease, complete closure was observed in 8% (n = 5) of patients with perianal fistulas, with 34% (n = 21) showing partial response. Treatment was maintained for a median of 6 months (IQR, 2-16). After a median clinical follow-up of 24 months (IQR, 15-57), the rate of treatment-related adverse events was 34%, correlating with blood drug concentrations (P = 0.021). Finally, 120 patients (84%) discontinued tacrolimus, usually due to absence or loss of response. Three patients (2%) were subsequently diagnosed with cancer. The overall rate of surgery was 39%, with a 33% colectomy rate in UC. CONCLUSIONS: Tacrolimus shows a clinical benefit in both CD and UC after 3 months of treatment, but its long-term effectiveness and frequent adverse events remain relevant issues in clinical practice.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Lago I, Castro-Poceiro J, Fernández-Clotet A, et al. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32181930. doi:10.1111/apt.15687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。